Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-158"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"cs"^^xsd:language2
lpv:document identification number	"en.20081022.17.3-158"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-1592
lpv:speaker	lp:Zuzana Roithová2
lpv:spokenAs	substitute; INTA (2007-01-31--2009-07-13)3 vice-chair; IMCO (2007-01-31--2009-07-13)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2004-09-15--2009-07-13)3 substitute; FEMM (2007-01-31--2009-07-13)3 member; EPP-ED (2004-07-20--2009-07-13)3 unknown; Křesťanská a demokratická unie - Československá strana lidová (2004-07-20--2009-07-13)3
lpv:translated text	"I must respond to today’s debate, in which I stated, naturally, that I warmly welcome this report. A requirement was included, however, for all drugs containing the same active ingredient to bear the same company name, in order to avoid patients becoming confused and taking excessively high doses. This may sound sensible to non-specialists, but drugs are constantly being innovated and, moreover, drugs which share the same or similar active ingredients may differ in a range of other constituents. To reproach the Commission for not ordering a standardisation of company names would be absurd, suggesting a failure to understand how the system works, regardless of what powers the European Union may have in general."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph